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Abstract
This chapter mainly introduces the physicochemical properties, physiological 
function, and metabolic pathway of low-density lipoprotein (LDL), with emphasis 
on the mechanism of atherosclerosis caused by LDL and the existing treatment 
methods. The content of this paper is detailed and comprehensive, including the 
latest research results in recent years. Different from the published articles, this 
paper adopts an innovative “tree” structure, with the disease development process 
as the main line and the molecular mechanism as the branch, showing the clini-
cal significance of the molecular mechanism. The main purpose of the author of 
this paper is to take LDL as an example, establish a multidimensional knowledge 
system, and strive to make the complex molecular mechanism vivid.
Keywords: low-density lipoprotein, metabolism, atherosclerosis,  
familial hypercholesterolemia, treatment
1. Introduction
In recent years, the research on abnormal metabolism of blood lipids has 
gradually increased, and the importance of blood lipid management in primary 
prevention and secondary prevention of cardiovascular diseases has been clarified. 
This is because dyslipidemia, as a major cardiovascular risk factor, is the common 
pathway of multiple pathogenic factors, mainly manifested as the qualitative and 
quantitative changes in low-density lipoprotein (LDL), attacking the endothelium, 
initiating an inflammatory response, promoting the occurrence and development 
of atherosclerosis, and ultimately producing cardiovascular events. Thus, the 
understanding of the quantitative and qualitative changes in LDL is the basis of 
atherosclerosis treatment and prevention.
2. Physicochemical characteristics and metabolic process of LDL
LDL is a spherical particle, core lipids of LDL particle are composed of choles-
terol ester (CE) and triglyceride (TG), an outer monolayer is composed of free cho-
lesterol (FC) and phospholipid (PL) including phosphatidylcholine (PC), and one 
molecule of apolipoprotein B100 surrounds the LDL particle [1]. Apolipoprotein 
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B-100 (apoB-100) is composed of the amphoteric α-helical domain and β-sheet 
domain alternately (NH2-βα1-β1-α2-β2-α3-coOH), in which β-sheet structure 
accounts for 40%, which is related to the stability of LDL particles, and α-helix 
accounts for 25%, which is related to the amphiphilicity of LDL particles and the 
potential of self-repair [2].
LDL is the plasma metabolite of very low-density lipoprotein (VLDL). Plasma 
lipoprotein lipase or liver lipase catalyzes the hydrolysis of triglyceride (TG) in 
VLDL particles. At the same time, under the action of cholesterol ester transfer 
proteins (CETPs), cholesterol ester (CE) of HDL is transferred to VLDL, and phos-
pholipids, apolipoprotein C (ApoC), and cholesterol are transferred to high-density 
lipoprotein (HDL) on the surface of VLDL. This process continues. In VLDL, TG 
decreases continuously, CE increases gradually, particles become smaller, and 
density increases gradually. First intermediate density lipoprotein (IDL) is formed, 
and then LDL is formed [3]. According to the formation process of LDL, it is easy 
to see that LDL is not a kind of particle but a class of particles with different sizes, 
densities, chemical composition, or different charges. In recent years, LDL particles 
have been divided into two phenotypes: type A (large and light LDL), LDL particle 
diameter ≥25.5 nm, and type B (small and dense LDL, sd-LDL), LDL particle 
diameter <25.5 nm. Compared with type A LDL, sd-LDL has a stronger ability to 
cause atherosclerosis and has been identified for a long time as a new risk factor of 
cardiovascular disease by the American Cholesterol Education Program and Adult 
Treatment Program III (NCEPIII) [4].
Natural LDL (nLDL) is in charge of the transport of endogenous cholesterol, 
and its metabolic process is the transport process of endogenous cholesterol. 
Among them, two-third were metabolized through the LDL receptor pathway [5]. 
LDL receptor (LDLR) is widely distributed in the whole body, especially on the cell 
membrane surface of the liver, adrenocortical, ovarian, testicular, and arterial wall, 
and specifically binds to ApoB100 on the surface of LDL. Internalization causes the 
membrane at the junction to sink in for endocytosis. Under the action of the proton 
pump (H+ -ATPase), the pH of endocytotic vesicle contents decreased, and LDL is 
separated from the receptor and fused with the lysosome. ApoB100 is decomposed 
into amino acids by a lysosomal proteolytic enzyme, and CE is hydrolyzed into free 
cholesterol and fatty acids by cholesterol esterase for cell utilization.
The remaining one-third is cleared by the mononuclear macrophage pathway. As 
a major member of innate immunity, macrophages are endowed with an advanced 
arsenal of sensors, composed of various pattern-recognition receptors (PRR). It is 
able to identify and bind foreign substances or altered substances to inactivate and 
degrade them. Therefore, the monocyte–macrophage clearance pathway is mainly 
aimed at LDL, which has changed its structure for a variety of reasons. It can also be 
called modified LDL (mLDL). mLDL specifically binds to the scavenger receptors 
(SRs) on the surface of macrophages and is subsequently removed. The half-life of 
plasma LDL in normal people is 2–4 days.
The cells prepare their cholesterol needs via two pathways: an exogenous 
pathway mediated with the LDLR and an endogenous pathway activated with the 
substrates of mevalonate and HMG-CoA reductase [6]. When the intracellular 
cholesterol level is too high, sterol regulatory element-binding protein (SREBP), 
a nuclear transcription factor, is activated, which inhibits the expression of LDL 
receptor gene from the transcription level, inhibits the synthesis of the receptor 
protein, and reduces the further uptake of LDL by the cell [7]. It is suggested that 
the simple increase of the nLDL-C level cannot fully explain the occurrence of 
atherosclerotic disease. More significantly, contrary to LDLR, SR expression is not 
inhibited by elevated intracellular cholesterol levels [1]. Then, when the number of 
modified LDL absorbed by macrophages through SRs far exceeds their scavenging 
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capacity, significant cholesterol accumulation will occur in macrophages, and then 
macrophages will be transformed into foam cells, which is a key link in the occur-
rence of atherosclerosis [8, 9].
3. LDL modification: endowing LDL with special biological activity
3.1  Changes in lipid composition of LDL particles and primary structure  
of apoB-100
At present, more research is placed on the effects of oxidation and glycosylation 
on LDL.
LDL oxidation: when circulating LDL is out of extremely high levels, oxidized 
LDL (ox-LDL) is rarely found in circulation due to the presence of plasma antioxi-
dants and vitamin C. In this case, the oxidation of LDL occurs mainly in the arterial 
wall. Vascular wall cells (endothelial cells, smooth muscle cells, and macrophages), 
stimulated by the attack factors, produce and release a large number of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). Free radicals rapidly 
oxidize the polyunsaturated fatty acids (PUFAs) on the surface of LDL into fatty 
acid fragments [10, 11]. This modification is produced in the surface of the LDL 
particles, so the physical and chemical properties of LDL change little. We call this 
LDL the “minimum modified LDL,” which retains the affinity for the LDL receptor. 
Then the “minimum modified LDL” activates the endothelial anti-apoptosis signal-
ing pathway, induces endothelial cells to express tissue factors and chemokines, 
promotes the aggregation of inflammatory cells, triggers an inflammatory reaction, 
generates a large number of free radicals, and leads to the continuous oxidation of 
LDL. Continuous oxidation further converts fatty acid fragments into aldehydes, 
and aldehydes interact with the lysine residues of apoB-100 to form new antigenic 
determinants, inducing the formation of autoantibodies [12, 13]. After complete 
oxidation, ox-LDL completely loses its affinity to LDLR and binds specifically to the 
scavenger receptors (SRs) [14].
With an extremely high level of circulating LDL, the antioxidants in the body 
are insufficient to maintain the antioxidant protection of nLDL. And nLDL oxi-
dizes rapidly even without strong attack factors. Meanwhile, high levels of LDL, in 
turn, promote the binding of NO with hydrogen peroxide to produce peroxynitrite 
(ONOO-), which is a strong oxidant and constantly attacks endothelial cells, result-
ing in endothelial dysfunction [15, 16].
LDL glycosylation: LDL glycosylation is a nonenzymatic reaction, and the reac-
tion rate depends on the level of glucose and the duration of exposure [17]. The 67th 
amino acid region of the N-terminus of apoB-100 is the main site of glycosylation 
and also the attachment site of LDLR. Glycosylation at this site reduces the affinity 
of LDL to LDLR, promotes the uptake of LDL by SRs on the surface of macro-
phages, and induces the formation of foam cells. Glycosylation of LDL enhances the 
susceptibility to further oxidation of LDL. In addition, the glycosylation process 
is accompanied by the production of free radicals, which often result in the simul-
taneous existence of LDL glycosylation and LDL oxidation [18]. This is among the 
causes of peripheral vascular disease in patients with advanced diabetes.
3.2  Changes in lipid content of LDL particles and secondary structure  
of apoB-100
The conformation of apoB-100 on the surface of LDL is more dependent on 
the physical and chemical state of the lipid core, which is linked to the shape and 
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size of the LDL particles. Related experiments have found that the conformation 
of ApoB-100 is associated with the coverage of the interfacial area effect existing 
at the LDL particle-water solution interface. The coverage of the interfacial area 
effect increases with the decrease of LDL particle size, which can be regarded as 
an adaptive conformation change. This change is to avoid or minimize the contact 
between hydrophobic protein residues and aqueous solutions largely. It also ensures 
the stable existence of cholesterol in a hydrophilic environment and leads to suc-
cessfully complete the targeted transport. However, this conformation regulation 
also causes more β-sheet domains to be parallel to the phospholipid monolayer of 
LDL, making it more vulnerable to adverse factors [19]. This may be one reason why 
sd-LDL with higher atherosclerosis is more easily oxidized.
The effect of oxidative modification on the secondary structure of LDL is mainly 
characterized by the destruction of β-sheet domain in the initial stage, resulting in 
the generation of disordered rings and corners. This change reduces the proportion 
of β-sheet in ApoB-100 and destroys the stability of LDL, but the alpha-helix ratio 
increases, triggering the self-repairing potential of apoB-100. At this point, the 
physical and chemical properties of LDL particles changed very little. When the 
oxidant continuously penetrates into the core, the physical state and accumulation 
mode of the lipid inside the hydrophobic core change, leading to the loss of the 
secondary structure of apoB-100, and the physical and chemical properties of LDL 
completely change [19].
In summary, compared to nLDL, mLDL has the following characteristics:
• the negative charge on the surface of particles is increased,
• the particle density is increased,
• due to the oxidation of lipids, polyunsaturated fatty acids decreased, and the 
contents of hemolytic lecithin, cholesterol oxide, and lipid hydroperoxide 
increased,
• ApoB100 is fragmented,
• reduced affinity with LDLR and specifically binds to scavenger receptors 
(SRs),
• acquired immunogenicity.
4.  Modified LDL (mLDL) is involved in the formation of atherosclerotic 
lesions
Combined with the current known research results, the concept that the LDL-C 
level is critical to the occurrence and development of atherosclerotic lesions is too 
broad. It is better to say that the increase of the mLDL level caused by LDL qualita-
tive change and quantitative change is the “turning point” of the entire event. Now, 
let us reexamine the role of mLDL in this process by combining the macro with the 
micro.
The physiological process of life can be divided into two levels: the basic 
physiological process and the complex regulatory network. Abnormal physi-
ological processes are at the root of all diseases. According to the level of abnor-
mality, we divide the disease into functional disorder and congenital defect.
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4.1  Functional disorder: abnormal regulation of the network and damage to the 
ability to retain stability
The main purpose of the regulation network is to check and balance the basic 
physiological process and maintain the local and overall steady state. According 
to the understanding of atherosclerotic lesions, we regard the homeostasis main-
tenance here as the balance between injury factors and protective factors, and the 
balance can be broken for the following reasons:
4.1.1 Excessive damage factors
Poor lifestyle such as smoking and alcohol abuse as well as basic diseases such as 
hyperglycemia, insulin resistance, and hypertension damage vascular endothelial 
cells, causing oxidative stress on the blood vessel wall and producing a large number 
of free radicals (ROS and RNS) [11, 20]. There is a close interaction between LDL and 
vascular endothelial cells, followed by oxidative modification of LDL to form ox-
LDL. Ox-LDL is most likely to remain in the intima-media than nLDL. And ox-LDL, 
which is stuck in the middle layer of the intima, affects the activity of endothelial cells 
(ECs) by changing the level of microRNAs and other epigenetic factors [21, 22]. It can 
induce the inflammatory activation of endothelial cells mediated by α5β1 integrity 
and promote the production of vascular cell adhesion molecule-1 (VCAM-1). These 
cytokines attract monocytes to adhere to the designated location, promote the transen-
dothelial transport of monocytes, enable them to accumulate in the endometrium, and 
differentiate into macrophages [23]. This process upregulates the expression of SRs 
on the surface of macrophages and promotes the uptake of ox-LDL by macrophages. 
At the same time, ox-LDL acts as an antigen to form an immune complex with auto-
antibodies, and then the immune complex is recognized and internalized by the Fcγ 
receptor on the surface of macrophages [24, 25]. These two mechanisms are associated 
with the formation of foam cells. LPC, the main phospholipid component of ox-LDL, 
plays a pro-inflammatory role by regulating the function of a series of immune cells 
(monocytes, macrophages, T cells, dendritic cells) and vascular cells (endothelial cells, 
vascular smooth muscle cells). It also acts as a ligand for specific G protein-coupled 
receptors, activating several atherogenic signal transduction pathways [26].
4.1.2 Abnormal protective factors
At present, the research is mainly about the protective effect of nitric oxide 
(NO)-based antioxidants and the innate immunity of mononuclear macrophages.
NO, as a signal transduction molecule with free radical properties, can maintain 
vascular diastolic tension and regulate lipid peroxidation reaction, which subse-
quently changes the expression of pro-inflammatory genes in endothelial cells. 
When NO synthesis is blocked, the balance between reactive oxygen species (ROS) 
released by stressed tissues and antioxidants is broken, and ox-LDL is produced 
in large quantity. Stress also induces endothelial dysfunction and permeability of 
endothelial changes. The main consequence of this series of changes is the accumu-
lation of ox-LDL in the subendothelial area [11, 15, 16].
As the principal carrier of circulating cholesterol, LDL contains a certain amount of 
polyunsaturated fatty acid (PUFAs), which is very sensitive to oxidative modification 
and is prone to structural changes [10]. In the normal state, innate immunity is activated 
to clear the ox-LDL produced in the physiological process. When the immune system is 
extremely responsive, macrophages play an antigen-presenting role and stimulate the 
proliferation of helper T lymphocytes, and the helper T lymphocytes produce specific 
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cytokines, realizing cross-dialog between different immune cell groups and initiating 
adaptive immunity. All the mechanisms work together to launch a sharp attack on ox-
LDL, forming a chronic inflammatory process unique to atherosclerotic diseases [27].
The persistent inflammatory response stimulates smooth muscle cells to migrate 
to the intima-media, proliferate, and secrete large amounts of collagen, and the lesion 
enters the fibrous plaque stage. In this stage, intima thickening and remodeling first 
lead to increasing arterial wall stiffness and increased interfacial pressure in the 
environment where LDL is located, which promotes secondary structural changes of 
apoB-100 [28]. Secondly, the ability of regional oxygen diffusion was weakened, and 
the intermediate area of atherosclerotic lesions and intima-media showed ischemia 
and hypoxia. For the purpose of compensation, glycolysis becomes the primary 
mode of cell productivity in this region. This metabolic process produces lactic acid, 
which leads to extracellular space acidification. The state of regional low PH value is 
beneficial to the activation of macrophages and the upregulation of ox-LDL receptor 
(mainly LOX-1) expression in macrophages. The upregulated LOX-1 increases the 
lipid absorption of macrophages and promotes the formation of foam cells [29]. In 
addition, upregulated LOX-1 increases endothelial permeability and promotes the 
migration of ox-LDL to subendothelial space by reducing the expression of des-
moglein-1 (DSG-1) and desmocollin-2 (DSC-2) [30, 31]. Under the stimulation of 
ox-LDL, the above process is repeated, the fiber cap becomes thickened, the declin-
ing foam cells form a necrotic lipid core, and the lesion enters the atherosclerotic 
plaque stage. When the compensatory arterial dilatation is unable to compensate for 
the stenosis caused by plaques protruding into the lumen, blood flow changes. The 
clinical manifestation is stable coronary syndrome. After that, if the disease continues 
to evolve, under the action of mechanical stimulation or inflammatory mediators, the 
fibrous cap becomes thinner, and local macrophages are activated, followed by focal 
necrosis, plaque rupture, content flow out, and thrombosis. The initiation of this 
process is the main cause of acute cardiovascular events.
Most of the atherosclerotic lesions caused by functional disorders progress slowly, 
and the clinical symptoms appear relatively late, which is mainly due to the existence 
of a series of compensation mechanisms, from the molecular level to the organ level, 
forming the natural defense line of the body. The breakthrough of the line of defense 
is characterized by micro decompensation, which corresponds to the progress of the 
disease at the macro level. The occurrence of cardiovascular events represents the loss 
of the ability to maintain stability, and treatment such as stenting can quickly relieve 
symptoms. However, this does not solve problems fundamentally, and it is necessary 
to effectively control the concentration of LDL particles having atherogenic proper-
ties. Combined with clinical experience, controlling the level of circulating LDL-C is 
the only effective method at present. Fortunately, the basic physiological processes 
of these patients are complete, and their regulatory network still exists. The focus of 
treatment is on using drugs to help the body to build a new balance. On the basis of 
a healthy lifestyle, adequate statin administration is effective in controlling LDL-C 
levels. For patients with moderate- or high-dose statin intolerance, the use of statins 
can be reduced by combining with ezetimibe or proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors, which can delay or even prevent the progression of 
the disease and largely avoid cardiovascular endpoint events [32].
4.2 Congenital defect: familial hypercholesterolemia (FH)
Familial hypercholesterolemia is an autosomal dominant genetic disease char-
acterized by high plasma levels of low-density lipoprotein cholesterol (LDL-C) 
and premature coronary heart disease, mainly caused by mutations in low-density 
lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase 
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subtilisin/kexin type 9 genes. The first half of this article has introduced how 
extremely high levels of LDL-C can initiate LDL modification and attack the endothe-
lium, which will not be described here. The high level of LDL-C in patients with FH 
since childhood is rooted in the damage to the basic physiological processes, which are 
genetically determined and inherent defects. Moreover, since the expression products 
of related genes are widely distributed under normal conditions, gene abnormalities 
also lead to regulatory network defects with compensation function damage, and 
the disease progresses rapidly in a short time. The traditional lipid-lowering method 
based on statins acts on the intracellular cholesterol synthesis process, which depends 
on the integrity of the basic physiological process, so it cannot effectively control 
the LDL-C level of FH patients. The key point of FH treatment is to make up for the 
defects in the basic physiological process and ensure survival. The discovery of PCSK9 
inhibitors is a boon to such patients. PCSK9 combines with LDLR to promote LDLR 
degradation and interrupt the recycling of LDLR. Combined with statins, it can 
effectively control the LDL-C level of most FH patients. The reason why most but not 
all FH patients benefit is that this precision also leads to the poor treatment effect of 
PCSK9 inhibitor on LDLR-deficient FH homozygous [32–36].
5. Conclusions
LDL participates in the whole process of the formation and development of 
atherosclerotic lesions in the form of mLDL until plaque rupture, thrombosis, and 
cardiovascular events occur. The understanding of the characteristics of atheroscle-
rosis caused by LDL should be built on the understanding of individual context. At 
present, a single LDL-C level has been impossible to accurately predict the progres-
sion of atherosclerotic lesions. The application value of mLDL, sd-LDL, etc. in the 
clinical practice needs to be further explored in the future.
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